3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel.
A. Cipriani, P. Cowen
The Lancet Psychiatry June 1, 2018 DOI: 10.1016/s2215-0366(18)30170-6 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | MDMA Psychedelic-assisted therapy PTSD |
Abstract
Published online at: https://doi.org/10.1016/S2215-0366(18)30170-6 Eligible users can access the full text via NHS OpenAthens at [https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2215036618301706] (login required).
Citations in the library
Cited by 4
- The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Medical Hypotheses 2021
- MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats Translational Psychiatry May 3, 2022
- MDMA-assisted psychotherapy in the treatment of PTSD in adults – literature review Pharmacotherapy in Psychiatry and Neurology 2023
- Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor. Neuropharmacology February 16, 2021
Cites 3
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- Mood and cognitive effects of ± 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week‐end ‘high’ followed by mid‐week low Addiction July 1, 1997
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry April 5, 2016